Signature

PTO/SB/21 (08-03) Approved for use through 08/30/2003, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to collection of information unless it displays a valid OMB control number. Application Number 10/764,075 **TRANSMITTAL** Filing Date 01/23/04 **FORM** First Named Inventor Thomas M. Briese Art Unit (to be used for all correspondence after initial filing) 1645 **Examiner Name** to be assigned Attorney Docket Number 5199-87 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Technology Center (TC) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a **Proprietary Information** After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer **Extension of Time Request** Identify below): Return receipt postcard Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Todd Holmbo, Reg. No. 42,665 Individual name Signature Date 9/2/04 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Ping Xiao Date 9/2/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas M. Briese, et al.,

Docket No.:

5199-87

Serial No.:

10/764,075

Examiner:

to be assigned

Filed:

January 23, 2004

Group Art Unit: 1645

Title:

METHODS AND KITS FOR DETECTING SARS-ASSOCIATED

CORONAVIRUS

September 2, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 CFR §1.97(b)</u>

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, applicant hereby notifies the U. S. Patent and Trademark Office of the following documents, which are listed on the attached PTO/SB/08B form. The examiner may deem these documents to be relevant to patentability of the claims of the above-identified application. A Copy of the document is enclosed for the examiner's convenience.

The submission of the listed documents is not intended as an admission that any of the documents constitute prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Applicants respectfully request that the listed documents be considered by the examiner and be made of record in the present application and that initialed a copy of form PTO/SB/08B be returned in accordance with MPEP §609.

It is understood that no fee is necessary for submission of this Information Disclosure Statement, as it is being filed before the later of three months from the filing date or the mailing of the first Office Action on the merits. The Commissioner is hereby authorized to charge payment of any fees associated with this application or credit any overpayment to Deposit Account No. 02-4270.

Respectfully submitted,

Yodd Holmbo

Reg. No. 42,665

Attorney for Applicants

BROWN RAYSMAN MILLSTEIN

FELDER & STEINER LLP

163 Madison Avenue

P.O. Box 1989

Morristown, New Jersey 07962-1989

(973) 775-8930

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. NT & TSubstitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

4

Sheet

Complete if Known			
Application Number	10/764,075		
Filing Date	01/23/04		
First Named Inventor	Thomas M. Briese		
Art Unit	1645		
Examiner Name	to be assigned		
Attorney Docket Number	5199-87		

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*					
		Calza L., Manfredi R., Verucchi G., Chiodo F. "SARS: a new emergency in the world health"			
		Recenti Prog Med. 94(7-8): 284-294, 2003			
		Drosten et al., "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome"			
		N. Engl. J. Med., 348: 1967-1976, 2003			
		Kaiser et al., "Viral aetiology of acute respiratory illness in patients with suspected severe acute respiratory syndrome (SARS) in Swizerland"			
		Swiss Med. Wkly. 133: 400-401, 2003			
		Ksiazek et al., "A Novel Coronavirus Associated With Severe Acute Respiratory Syndrome"			
		N. Engl. J. Med., 348: 1953-1966, 2003			
		Kuiken et al., "Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome"			
		Lancet 362: 263-270, 2003			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. & Buestitute for form 1449/PTO Complete if Known **Application Number** 10/764,075 INFORMATION DISCLOSURE **Filing Date** 01/23/04 STATEMENT BY APPLICANT First Named Inventor Thomas M. Briese Art Unit 1645 (Use as many sheets as necessary) **Examiner Name** to be assigned Attorney Docket Number Sheet 4 5199-87 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Lee et al., "A major outbreak of severe acute respiratory syndrome in Hong Kong"	
		N. Engl. J. Med., 348: 1995-2005, 2003	
		Li G., Chen X. and Xu A. "Profile of specific antibodies to the SARS-associated coronavirus"	
		N. Eng. J. Med. 349: 5-6, 2003	
		Mazzulli et al., "Severe acute respiratory syndrome-associated coronavirus in lung tissue"	
		Emerg. Infect. Dis. 10: 20-24, 2004	
		Peiris et al., "Coronavirus as a possible cause of severe acute respiratory syndrome in Hong Kong"	
		Lancet, 361: 1319-1325, 2003	
		Poon, et al., "Early diagnosis of SARS coronavirus infection by real time Kf-PCR"	
		J. Clin. Virol. 28: 233-238, 2003	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ASLESSITUTE for form 1449/PTO		e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
1930	Application Number	10/764,075		
INFORMATION DISCLOSURE	Filing Date	01/23/04		
STATEMENT BY APPLICANT	First Named Inventor	Thomas M. Briese		
(Use as many sheets as necessary)	Art Unit	1645		
(Use as many sneets as necessary)	Examiner Name	to be assigned		
Sheet 3 of 4	Attorney Docket Number	5199-87		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Poutanen et al., "Identification of severe acute respiratory syndrome in Canada"	
		N. Engl. J. Med., 348: 1995-2005, 2003	
		Ren et al., "Detection of SARS-CoV RNA in stool samples of SARS patients by nest RT-PCR and its clinical value"	
		Zhongguo YiXue Ke Xue Yuan Xue Bao 25: 368-371, 2003	
		"SARS"	
		Weekly Epidemiological Record 78: 81-83, 2003	
		WHO Multicentre Collaborative Network for Severe Acute Respiratory Syndrome (SARS) Diagnosis. A multicentre collaboration to investigate the	
		cause of severe acute respiratory syndrome.	
		Lancet 361: 1730-1733, 2003	

Examiner	Date	· · · · · · ·
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/PTO			Complete if Known		
- Duooa.	10 10 10 11 14 10 11 10			Application Number	10/764,075	
INF	ORMATION	DIS	CLOSURE	Filing Date	01/23/04	
STA	STATEMENT BY APPLICANT			First Named Inventor	Thomas M. Briese	
	(lles se meny che	oto oo n	ecoccond	Art Unit	1645	
(Use as many sheets as necessary)			ecessary)	Examiner Name	to be assigned	
Sheet	4	of	4	Attorney Docket Number	5199-87	

Examiner Initials*	Cite No. ¹	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WHO Update 31, Coronavirus never before seen in humans is the cause of SARS, April 16, 2003	
		WHO Weekly Epidemiological Record, No. 12, March 21, 2003	
		Wu et al., "Establishment of a fluorescent polymerase chain reaction method for the detection of the SARS-associated coronavirus and	
		its clinical application".	
		Chin. Med. J. 116: 988-990, 2003	
		Yam et al., "Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel	
		coronavirus".	
		J. Clin. Microbiol. 41: 4521-4524, 2003	
		Zhou et al., "Identification and molecular cloning and sequence analysis of a novel coronavirus from patients with SARS by RT-PCR".	
		Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 17: 137-139, 2003	

Examiner	_	Date	- · · · · ·
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.